Replimune Group, Inc.
Financials
Valuation Metrics
Replimune Group, Inc.'s Market Cap is $1.84B. At end of 2025 it was $896M. Ranked #2112 of 3,118 in US market (top 68%), #812 of 1,474 on NASDAQ (top 55%), #148 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,112/3,118 Sec#148/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-271M | US—/3,118 Sec—/265 |
| Total Assets | $374M | US#2,857/3,118 Sec#192/265 |
| Net Assets | $205M | US#2,662/3,118 Sec#189/265 |
| Employees | 465 | US#2,290/3,118 Sec#84/265 |
| Value | ||
| P/B | 8.97x | US#2,533/3,118 Sec#186/265 |
| FCF Yield | -13.39% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -132.35% | US#2,810/3,118 Sec#211/265 |
| ROA | -72.48% | US#3,028/3,118 Sec#242/265 |
| Financial Health | ||
| Debt Ratio | 82.61% | US#917/3,118 Sec#154/265 |
| Total Debt | $127M | US#2,365/3,118 Sec#109/265 |
| FCF | $-246M | US#2,817/3,118 Sec#226/265 |
| Cash | $308M | US#1,387/3,118 Sec#80/265 |
| Current Ratio | 7.11x | US#347/3,118 Sec#107/265 |
| Performance | ||
| 1Y Return | 100.26% | US#289/3,118 Sec#55/265 |
| 1M Return | 49.08% | US#64/3,118 Sec#9/265 |
| From 52W High | -0.97% | US#300/3,118 Sec#24/265 |
| 1Y MDD | -84.16% | US#3,069/3,118 Sec#252/265 |
| Trading | ||
| Volume | 7,128,145 shares | US#586/3,118 Sec#43/265 |
| Trading Value | $135M | US#1,158/3,118 Sec#68/265 |
| Per Share | ||
| EPS | $-2.88 | US—/3,118 Sec—/265 |
| BPS | $2.17 | US#2,557/3,118 Sec#174/265 |
Company Info
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.